Please select the option that best describes you:
Topics:
Internal Medicine • Rheumatology • Systemic sclerosis • Interstitial lung disease • Nintedanib • Pulmonology
What is the role of nintedanib in the treatment of SSc-ILD?
The SENSCIS trial was published in 2019 on efficacy of this agent. However, it's not clear where this should be in the treatment algorithm: Monotherapy vs combination? First line or second line?
Answer from: at Community Practice
Nintedanib has shown to be effective for treating patients with ILD associated with systemic sclerosis, as the annual rate of decline in FVC was lower with nintedanib than with placebo (SENSCIS trial). However, the majority of patients treated with nintedanib in this trial were also on MMF therapy. ...
Sign in or Register to read more
Answer from: at Community Practice
Dr. McMahan's answer supports the striking difference in the primary endpoint selection in the trial designs and results between nintedanib (Distler et al., PMID 31112379) and both Scleroderma Lung Study (SLS) I and II.Equally striking were the statistically significant results in the secondary endp...